• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[输血程序的安全性:其各个方面、各个阶段]

[Safety of transfusion procedures: its various aspects, its various stages].

作者信息

Menault M

出版信息

Rev Prat. 1989 Sep 11;39(20):1762-5.

PMID:2814259
Abstract

Despite considerable advances, transfusions still present major immunological and infectious dangers. Immunological accidents can be perfectly prevented by adhering to strict rules as regards the immediate risk, haemolysis, and satisfactorily prevented as regards late allo immunization. Safety concerning the transmission of viral or parasitic diseases is far from being absolute in spite of increasingly sophisticated tests performed on donors. This implies that transfusions should be restricted to clearly defined situations where the potential advantage overrides the risk and where the safest product can be chosen. This type of safety requires high quality blood products reflecting the high level of organization and technique of the Transfusion Centre. Finally, autotransfusion, the rules of which must be well-defined, may be an alternative in certain cases representing up to 10 p. 100 of all transfusions.

摘要

尽管取得了长足的进步,但输血仍存在重大的免疫和感染风险。通过遵守关于即时风险、溶血的严格规定,可以完美预防免疫事故,并且在迟发性同种免疫方面也能得到有效预防。尽管对献血者进行了越来越复杂的检测,但关于病毒或寄生虫疾病传播的安全性远非绝对。这意味着输血应仅限于明确界定的情况,即潜在益处超过风险且可以选择最安全产品的情况。这种类型的安全需要高质量的血液制品,这反映了输血中心的高度组织和技术水平。最后,自身输血(其规则必须明确界定)在某些情况下可能是一种替代方法,在所有输血中占比高达10%。

相似文献

1
[Safety of transfusion procedures: its various aspects, its various stages].[输血程序的安全性:其各个方面、各个阶段]
Rev Prat. 1989 Sep 11;39(20):1762-5.
2
[Current status of transfusion medicine].[输血医学的现状]
Infusionsther Klin Ernahr. 1985 Aug;12(4):163-9.
3
New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.用于使细胞血液成分中的传染性病原体失活的新技术以及血小板替代品的研发。
Baillieres Best Pract Res Clin Haematol. 2000 Dec;13(4):549-63. doi: 10.1053/beha.2000.0099.
4
[Targetted hemotherapy with special reference to the cellular components].[特别涉及细胞成分的靶向血液疗法]
Dtsch Med Wochenschr. 1990 Jul 6;115(27):1066-72. doi: 10.1055/s-2008-1065123.
5
Transfusion practices in the 1990s.20世纪90年代的输血实践。
Annu Rev Med. 1991;42:297-309. doi: 10.1146/annurev.me.42.020191.001501.
6
[Platelet transfusion: products, indications, dose, threshold and efficacy].[血小板输注:产品、适应证、剂量、阈值及疗效]
Transfus Clin Biol. 2009 May;16(2):118-33. doi: 10.1016/j.tracli.2009.04.001. Epub 2009 May 13.
7
Transfusion medicine and safety.
Biologicals. 2009 Apr;37(2):62-70. doi: 10.1016/j.biologicals.2009.01.006. Epub 2009 Feb 20.
8
[Viral safety concept: application to blood and blood products].
Rev Prat. 2005 Nov 30;55(18):2033-8.
9
Pathogen reduction technologies: what are the concerns?病原体灭活技术:有哪些担忧?
Vox Sang. 2004 Jul;87 Suppl 2:84-9. doi: 10.1111/j.1741-6892.2004.00459.x.
10
Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.荷兰血小板输注病原体灭活的成本效益
Transfus Med. 2005 Oct;15(5):379-87. doi: 10.1111/j.1365-3148.2005.00609.x.